Nuvalent Company Leadership

NUVL Stock  USD 102.09  0.90  0.87%   
Nuvalent's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Nuvalent suggests that most insiders are panicking. Nuvalent employs about 218 people. The company is managed by 15 executives with a total tenure of roughly 509 years, averaging almost 33.0 years of service per executive, having 14.53 employees per reported executive.

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2026-01-22Deborah Ann MillerDisposed 14300 @ 110.16View
2026-01-21Deborah Ann MillerDisposed 700 @ 109.84View
2026-01-06James Richard PorterDisposed 9543 @ 97.16View
2026-01-05Christopher Durant TurnerDisposed 4236 @ 97.32View
2025-12-08Alexandra BalcomDisposed 7084 @ 110.32View
2025-11-24James E FlynnDisposed 742574 @ 95.44View
2025-11-18Alexandra BalcomDisposed 729 @ 104.26View
2025-11-17Alexandra BalcomDisposed 20000 @ 99.45View
2025-10-30Deborah Ann MillerDisposed 21800 @ 103.16View
Monitoring Nuvalent's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.

Nuvalent Management Team Effectiveness

The company has return on total asset (ROA) of (0.2296) % which means that it has lost $0.2296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3879) %, meaning that it created substantial loss on money invested by shareholders. Nuvalent's management efficiency ratios could be used to measure how well Nuvalent manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.22. Return On Capital Employed is expected to rise to -0.28 this year. At this time, Nuvalent's Debt To Assets are quite stable compared to the past year.
The value of Common Stock Shares Outstanding is expected to slide to about 49 M. Net Loss is expected to rise to about (70 M) this yearThe majority of Nuvalent outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nuvalent to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nuvalent. Please pay attention to any change in the institutional holdings of Nuvalent as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
71.8 M
Current Value
72.1 M
Avarage Shares Outstanding
50.1 M
Quarterly Volatility
17.7 M
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as Nuvalent in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Nuvalent, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Nuvalent Workforce Comparison

Nuvalent is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 6,325. Nuvalent holds roughly 218 in number of employees claiming about 3% of equities under Health Care industry.

Nuvalent Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvalent insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvalent's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nuvalent insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2026-03-01
0.3
15
50
 292,500 
 111,796 
2025-12-01
0.3163
31
98
 315,402 
 991,830 
2025-09-01
0.3962
21
53
 160,320 
 317,778 
2025-06-01
0.9412
32
34
 188,442 
 248,000 
2025-03-01
0.42
21
50
 572,120 
 279,916 
2024-12-01
0.3111
14
45
 165,165 
 2,524,114 
2024-09-01
0.1753
17
97
 119,034 
 362,655 
2024-06-01
0.4833
29
60
 101,880 
 346,500 
2024-03-01
0.6818
15
22
 652,433 
 1,030,166 
2023-12-01
0.3
12
40
 147,041 
 514,082 
2023-09-01
0.3889
14
36
 67,330 
 134,660 
2023-06-01
0.6216
23
37
 184,767 
 69,534 
2023-03-01
0.5882
10
17
 1,009,580 
 42,300 
2022-12-01
0.2564
10
39
 865,821 
 242,296 
2022-09-01
0.4286
3
7
 68,404 
 24,332 
2022-06-01
13.0
13
1
 260,000 
 14,513 
2022-03-01
4.5
9
2
 831,400 
 8,400 
2021-09-01
0.9444
17
18
 20,232,638 
 100,043,254 

Nuvalent Notable Stakeholders

A Nuvalent stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nuvalent often face trade-offs trying to please all of them. Nuvalent's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nuvalent's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Prof ShairFounder BoardProfile
James PorterPresident CEOProfile
Ruth AdamsSenior OperationsProfile
Joshua HoranSenior ChemistryProfile
Chelcie ListerSenior CommunicationsProfile
Christopher MDChief OfficerProfile
Darlene NociChief OfficerProfile
Jessie LinSenior ManagementProfile
Matthew MBASenior ResourcesProfile
Perrin BSSenior StrategyProfile
John SogliaSenior DevelopmentProfile
Deborah JDChief SecretaryProfile
Benjamin LaneSenior OperationsProfile
Henry PelishSenior DiscoveryProfile
Matthew MetivierSenior ResourcesProfile
String symbol = request.getParameter("s");

About Nuvalent Management Performance

The success or failure of an entity such as Nuvalent often depends on how effective the management is. Nuvalent management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nuvalent management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nuvalent management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.30)(0.28)
Return On Assets(0.21)(0.22)
Return On Equity(0.28)(0.27)

Nuvalent Workforce Analysis

Traditionally, organizations such as Nuvalent use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nuvalent within its industry.

Nuvalent Manpower Efficiency

Return on Nuvalent Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.2M
Net Loss Per Executive17.4M
Working Capital Per Employee4.9M
Working Capital Per Executive71.9M
When determining whether Nuvalent is a strong investment it is important to analyze Nuvalent's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nuvalent's future performance. For an informed investment choice regarding Nuvalent Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvalent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. Anticipated expansion of Nuvalent directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Nuvalent assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(5.33)
Return On Assets
(0.23)
Return On Equity
(0.39)
Understanding Nuvalent requires distinguishing between market price and book value, where the latter reflects Nuvalent's accounting equity. The concept of intrinsic value - what Nuvalent's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Nuvalent's price substantially above or below its fundamental value.
It's important to distinguish between Nuvalent's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nuvalent should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nuvalent's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.